Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1082938.RAZSrKu_yNIUmrC0_aT0F9B9eOVMghOEe5RUGAUj8A_cc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1082938.RAZSrKu_yNIUmrC0_aT0F9B9eOVMghOEe5RUGAUj8A_cc130_assertion type Assertion NP1082938.RAZSrKu_yNIUmrC0_aT0F9B9eOVMghOEe5RUGAUj8A_cc130_head.
- NP1082938.RAZSrKu_yNIUmrC0_aT0F9B9eOVMghOEe5RUGAUj8A_cc130_assertion description "[CtBP2-specific inhibitors, such as MTOB, may be effective adjunct therapies in the management of patients with CtBP2-positive ovarian carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1082938.RAZSrKu_yNIUmrC0_aT0F9B9eOVMghOEe5RUGAUj8A_cc130_provenance.
- NP1082938.RAZSrKu_yNIUmrC0_aT0F9B9eOVMghOEe5RUGAUj8A_cc130_assertion evidence source_evidence_literature NP1082938.RAZSrKu_yNIUmrC0_aT0F9B9eOVMghOEe5RUGAUj8A_cc130_provenance.
- NP1082938.RAZSrKu_yNIUmrC0_aT0F9B9eOVMghOEe5RUGAUj8A_cc130_assertion SIO_000772 23730208 NP1082938.RAZSrKu_yNIUmrC0_aT0F9B9eOVMghOEe5RUGAUj8A_cc130_provenance.
- NP1082938.RAZSrKu_yNIUmrC0_aT0F9B9eOVMghOEe5RUGAUj8A_cc130_assertion wasDerivedFrom befree-2016 NP1082938.RAZSrKu_yNIUmrC0_aT0F9B9eOVMghOEe5RUGAUj8A_cc130_provenance.
- NP1082938.RAZSrKu_yNIUmrC0_aT0F9B9eOVMghOEe5RUGAUj8A_cc130_assertion wasGeneratedBy ECO_0000203 NP1082938.RAZSrKu_yNIUmrC0_aT0F9B9eOVMghOEe5RUGAUj8A_cc130_provenance.